{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:17:21Z","timestamp":1789399041376,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40261-021-01069-8","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T09:02:56Z","timestamp":1628758976000},"page":"829-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use"],"prefix":"10.1007","volume":"41","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"1069_CR1","unstructured":"Orphanet. Classic hairy cell leukemia. 2020. https:\/\/www.orpha.net. Accessed 26 Jul 2021."},{"key":"1069_CR2","unstructured":"Leukemia & Lymphoma Society. Hairy cell leukemia facts. 2018. https:\/\/www.lls.org. Accessed 26 Jul 2021."},{"issue":"6","key":"1069_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11864-020-00732-0","volume":"21","author":"J Paillassa","year":"2020","unstructured":"Paillassa J, Troussard X. Biology and treatment of hairy cell leukemia. Curr Treat Options in Oncol. 2020;21(6):44.","journal-title":"Curr Treat Options in Oncol."},{"key":"1069_CR4","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 2.2021: hairy cell leukemia. 2021. https:\/\/www.nccn.org. Accessed 26 Jul 2021."},{"issue":"6","key":"1069_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","volume":"145","author":"M Else","year":"2009","unstructured":"Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733\u201340.","journal-title":"Br J Haematol"},{"issue":"5","key":"1069_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553\u201360.","journal-title":"Blood"},{"issue":"1","key":"1069_CR7","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","volume":"25","author":"RJ Kreitman","year":"2020","unstructured":"Kreitman RJ, Pastan I. Contextualizing the use of moxetumomab pasudotox in the treatment of relapsed or refractory hairy cell leukemia. Oncologist. 2020;25(1):e170\u20137.","journal-title":"Oncologist"},{"issue":"7","key":"1069_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/bcp.14250","volume":"86","author":"D Kuruvilla","year":"2020","unstructured":"Kuruvilla D, Chia YL, Balic K, et al. Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. Br J Clin Pharmacol. 2020;86(7):1367\u201376.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1069_CR9","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","volume":"32","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768\u201377.","journal-title":"Leukemia"},{"key":"1069_CR10","unstructured":"European Medicines Agency. Lumoxiti (moxetumomab pasudotox) powder for concentrate and solution for solution for infusion: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/en. Accessed 26 Jul 2021."},{"key":"1069_CR11","unstructured":"AstraZeneca. LUMOXITI\u2122 (moxetumomab pasudotox-tdfk): US prescribing information. 2020. https:\/\/www.lumoxitihcp.com. Accessed 26 Jul 2021."},{"issue":"3","key":"1069_CR12","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","volume":"15","author":"RF Alderson","year":"2009","unstructured":"Alderson RF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation Pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res. 2009;15(3):832.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1069_CR13","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1069_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","volume":"14","author":"RJ Kreitman","year":"2021","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14(1):35.","journal-title":"J Hematol Oncol"},{"key":"1069_CR15","unstructured":"European Medicines Agency. Lumoxiti (moxetumomab pasudotox): EPAR assessment report. 2020. https:\/\/www.ema.europa.eu\/en. Accessed 26 Jul 2021."},{"issue":"5","key":"1069_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bjh.17055","volume":"191","author":"N Parry-Jones","year":"2020","unstructured":"Parry-Jones N, Joshi A, Forconi F, et al. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020;191(5):730\u20137.","journal-title":"Br J Haematol"},{"issue":"Suppl 5","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"v100","DOI":"10.1093\/annonc\/mdv200","volume":"26","author":"T Robak","year":"2015","unstructured":"Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v100\u20137.","journal-title":"Ann Oncol"},{"issue":"21","key":"1069_CR18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","volume":"131","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up. Blood. 2018;131(21):2331\u20134.","journal-title":"Blood"},{"issue":"Suppl 2","key":"1069_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/10428194.2011.566393","volume":"52","author":"MS Tallman","year":"2011","unstructured":"Tallman MS. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Leuk Lymphoma. 2011;52(Suppl 2):65\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1069_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5858\/2006-130-374-PPPOMR","volume":"130","author":"P Mhawech-Fauceglia","year":"2006","unstructured":"Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med. 2006;130(3):374\u20137.","journal-title":"Arch Pathol Lab Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01069-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T11:27:47Z","timestamp":1629977267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01069-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01069-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"25 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}